PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2017
CASE
AUTH/3004/12/17 Gilead

AUTH/3004/12/17: Director v Gilead – Clinical trial disclosure (Sovaldi) (No breach; outwith scope)

PMCPA case AUTH/3004/12/17 (Director v Gilead) concerning clinical trial disclosure for Sovaldi. Outcome: no breach; matter found to be outwith the scope…

2015
CASE
AUTH/2809/12/15 Amicus Therapeutics

AUTH/2809/12/15: Sanofi Genzyme v Amicus Therapeutics – pre-authorisation promotion to a patient organisation meeting

Amicus presented on investigational migalastat at a UK patient organisation network meeting. PMCPA ruled pre-authorisation promotion and lack of certification (Clauses 3.1,…

2014
CASE
AUTH/2690/1/14 Mitsubishi

AUTH/2690/1/14: Member of the public v Mitsubishi (Incivo) – out of scope / no breach

A member of the public complained to the PMCPA about Mitsubishi regarding clinical trial disclosure for Incivo. The matter was ruled outwith…

2013
CASE
AUTH/2627/8/13 Pfizer

AUTH/2627/8/13: Anonymous v Pfizer β€” meeting sponsorship (out of scope; no breach)

Anonymous complaint about Pfizer meeting sponsorship. PMCPA concluded the matter was outwith the scope of the ABPI Code, so no case report…

2006
CASE
AUTH/1822/4/06 ApoPharma ⭐ Case of the Week

Novartis v ApoPharma & Swedish Orphan: Ferriprox β€˜Life is getting longer’ claim, missing PI link, and public-facing patient newsletter issues (AUTH/1822/4/06, AUTH/1823/4/06)

Ferriprox banner and patient-newsletter content drew breaches for missing prescribing info link (HCP ad), unsubstantiated hanging comparison, and unbalanced public messaging encouraging…

2018
CASE
AUTH/3115/11/18 Novo Nordisk

Novo Nordisk advisory boards: high standards breach amid concerns over volume, format and embassy venue (AUTH/3115/11/18)

Anonymous complaint alleged repeated advisory boards were disguised promotion with excessive value. Panel found a breach of Clause 9.1 (high standards) due…

2007
CASE
AUTH/2021/7/07 Lundbeck

Lundbeck: amended Cipralex letter implied local health board endorsement (AUTH/2021/7/07 & AUTH/2024/7/07)

Two health boards said a Cipralex letter implied they endorsed use in GAD. A representative had altered a certified template and sent…

2006
CASE
AUTH/1800/2/06 AstraZeneca

AstraZeneca breached Code over Nexium meeting invitation email missing prescribing information (AUTH/1800/2/06)

A PCT complained about an emailed invite to an AstraZeneca-sponsored gastroenterology meeting that mentioned Nexium without prescribing information and without the generic…

2006
CASE
AUTH/1927/12/06 Sanofi

AUTH/1927/12/06: Doctor v Sanofi Pasteur MSD – Gardasil journal advertisement (appeal successful; no breach)

Doctor challenged Gardasil journal ad claims. Panel initially found one claim ambiguous/misleading, but on appeal the ruling was overturned. Final outcome: no…

2006
CASE
AUTH/1853/6/06 AstraZeneca ⭐ Case of the Week

AstraZeneca breached ABPI Code over Symbicort ad implying improved survival in COPD (AUTH/1853/6/06)

A BMJ Symbicort ad headed β€œImproving survival in COPD” was ruled misleading because it implied Symbicort improved survival, which was not substantiated.…

2015
CASE
Bayer

Bayer breached ABPI Code over ambiguous Xarelto renal impairment claim implying use β€œwith confidence”

A Pulse ad for Xarelto implied it could be used β€œwith confidence” in NVAF patients with renal impairment. PMCPA found the claim…

2010
CASE
AUTH/2375/12/10 GlaxoSmithKline Consumer

AUTH/2375/12/10: Curaprox v GlaxoSmithKline Consumer Healthcare (Corsodyl Mint Mouthwash detail aid) β€” No breach (outwith scope)

Curaprox complaint about a Corsodyl Mint Mouthwash detail aid. PMCPA found the matter outwith the scope of the Code; no breach. Undertaking…

2015
CASE
Novartis Pharmaceuticals UK

Novartis employee’s LinkedIn activity ruled promotional: sharing and β€˜liking’ content about Entresto and Cosentyx

A Novartis employee’s LinkedIn share and β€˜like’ activity was found to promote POMs to the public and lacked certification. Breaches were ruled…

2015
CASE
Pfizer

Pfizer: Legibility of prescribing information on PfizerPro website (Xeljanz, Sutent, Champix) β€” No breach

A UK health professional said prescribing information on PfizerPro for Xeljanz, Sutent and Champix was hard to read. Panel had some concerns…

2016
CASE
AUTH/2905/11/16 A Menarini ⭐ Case of the Week

AUTH/2905/11/16: Director v A Menarini β€” No breach (outwith scope of the Code)

PMCPA case AUTH/2905/11/16 (Director v A Menarini). Completed 7 March 2017. Outcome: No breach; matter considered outwith the scope of the ABPI…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training